Based on these findings, we have preliminarily confirmed in vitro that MM cell lines with a high ARRS are more tolerant to both protease inhibitors and inhibitors targeting the PI3K/Akt/mTOR signaling pathway. Here, AKT1 is linked to Miyoshi myopathy.